Cargando…

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks

Background: Decision-makers have implemented a variety of value assessment frameworks (VAFs) for orphan drugs in European jurisdictions, which has contributed to variations in access for rare disease patients. This review provides an overview of the strengths and limitations of VAFs for the reimburs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blonda, Alessandra, Denier, Yvonne, Huys, Isabelle, Simoens, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150002/ https://www.ncbi.nlm.nih.gov/pubmed/34054519 http://dx.doi.org/10.3389/fphar.2021.631527

Ejemplares similares

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

How to Assess the Value of Medicines?
por: Simoens, Steven
Publicado: (2010)

Toward a European definition for a drug shortage: a qualitative study
por: De Weerdt, Elfi, et al.
Publicado: (2015)

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
por: Pauwels, Kim, et al.
Publicado: (2019)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
por: Pauwels, Kim, et al.
Publicado: (2017)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

Time Investment in Drug Supply Problems by Flemish Community Pharmacies
por: De Weerdt, Elfi, et al.
Publicado: (2017)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
por: Car, Elif, et al.
Publicado: (2023)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

How to balance valuable innovation with affordable access to medicines in Belgium?
por: Simoens, Steven, et al.
Publicado: (2022)

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
por: Pauwels, Kim, et al.
Publicado: (2017)

A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies
por: Hoxhaj, Ilda, et al.
Publicado: (2020)

Guidance for Demonstrating the Societal Value of new Antibiotics
por: Simoens, Steven, et al.
Publicado: (2021)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study
por: Abdallah, Khadidja, et al.
Publicado: (2022)

Insights into European Drug Shortages: A Survey of Hospital Pharmacists
por: Pauwels, Kim, et al.
Publicado: (2015)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
por: Michelsen, Sissel, et al.
Publicado: (2020)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
por: van Overbeeke, Eline, et al.
Publicado: (2021)

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
por: Pauwels, Kim, et al.
Publicado: (2014)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
por: Kanters, Tim A., et al.
Publicado: (2017)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making
por: Saesen, Robbe, et al.
Publicado: (2020)

The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape
por: Moorkens, Evelien, et al.
Publicado: (2017)

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US
por: Whichello, Chiara, et al.
Publicado: (2019)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries
por: Bochenek, Tomasz, et al.
Publicado: (2018)

Market access of orphan drugs and the role of multi-criteria decision making
por: Simoens, Steven
Publicado: (2012)

How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer
por: Saesen, Robbe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2jg0ct79tgu5i26lfvvmof4t19